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Hamburg, CSSB-HZI at DESY, Notkestrasse 85, Bldg. 25LMAN1 is a glycoprotein receptor, mediating transfer from the ER to the ER–Golgi intermediate
compartment. Together with the co-receptor MCFD2, it transports coagulation factors V and VIII.
Mutations in LMAN1 and MCFD2 can cause combined deﬁciency of factors V and VIII (F5F8D). We
present the crystal structure of the LMAN1/MCFD2 complex and relate it to patient mutations. Cir-
cular dichroism data show that the majority of the substitution mutations give rise to a disordered
or severely destabilized MCFD2 protein. The few stable mutation variants are found in the binding
surface of the complex leading to impaired LMAN1 binding and F5F8D.
Structured summary:
MINT-7557086: lman1 (uniprotkb:P49257) and mcfd2 (uniprotkb:Q8NI22) bind (MI:0407) by X-ray crys-
tallography (MI:0114)
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Combined deﬁciency of coagulation factors V and VIII (F5F8D) is
an autosomal recessive bleeding disorder, with plasma levels of
coagulation factors FV and FVIII reduced to 5–30% of normal levels
[1,2]. This is due to mutations in the genes coding for either LMAN1
(lectin mannose-binding protein 1, also known as ERGIC-53) [3] or
MCFD2 (multiple coagulation factor deﬁciency 2) [4]. FVIII inter-
acts with the LMAN1/MCFD2 complex, while the B-domain deleted
form of FVIII exhibits reduced binding [5]. LMAN1/MCFD2 complex
formation and FVIII binding are calcium ion dependent [6–8].
LMAN1 protein was originally identiﬁed as a marker for the ER–
Golgi intermediate compartment (ERGIC). From the link to F5F8D,
LMAN1 was revealed to be a sorting receptor, mediating transport
of certain glycoproteins from the ER to the ERGIC [8]. LMAN1 exists
as homohexamers that cycle between the ER and the ERGIC [9],
binding correctly folded glycosylated cargo proteins, including FV
and FVIII, in the ER, recruiting the cargo for package into COPII
(coat protein II) coated vesicles and transport to the ERGIC. Many
proteins have been shown to act as cargo for LMAN1 besides FVchemical Societies. Published by E
Biochemistry and Biophysics,
ckholm, Sweden.
du Vercors, 69367 Lyon cedex
Research and University of
b, 22607 Hamburg, Germany.and FVIII e.g. cathepsin Z and cathepsin C [8,10], a1-antitrypsin
[11], and sulfatase modifying factor 1 [12].
LMAN1 is a type-1 transmembrane protein containing an ER
translocation signal sequence, a lumenal, a transmembrane, and
a short cytoplasmic domain. The lumenal domain can be divided
into an N-terminal carbohydrate recognition domain (CRD) (resi-
dues 31–285) and a membrane-proximal stalk domain. The CRD
is responsible for the calcium ion dependent binding of man-
nose-rich glycans. The stalk domain is thought to mediate oligo-
merization of LMAN1 [9], while the cytoplasmic tail contains a
COPII binding and an ER retrieval motif. The crystal structures of
the CRD, in apo- and Ca2+-bound form [13,14] show similarity to
Ca2+-dependent leguminous lectins, conﬁrming the role of LMAN1
as a glycoprotein receptor.
Mutations in MCFD2 cause the same clinical phenotype as
mutations in LMAN1 [2,4]. MCFD2 is only known to be required
for transport of FV and FVIII and may act as a speciﬁc recruitment
factor for these LMAN1 cargo proteins. MCFD2 encodes a highly
conserved 16-kDa soluble protein, which does not include motifs
for COPII binding or ER retrieval; correct localization of MCFD2 is
reliant on its binding to LMAN1. NMR studies [7] have shown that
MCFD2 is unfolded in the absence of Ca2+ ions and that Ca2+ bind-
ing induces folding of two C-terminal EF-hand motifs, explaining
the Ca2+ ion dependence for formation of the LMAN1–MCFD2
complex.
Presently, 32 mutations in LMAN1 [2,3,15] and 16 mutations in
MCFD2 leading to F5F8D have been identiﬁed [2,16,17]. To gainlsevier B.V. All rights reserved.
Table 1
Data collection and reﬁnement.
Data collection
Space group P61
Unit cell a = 56.6 Å, c = 396.9 Å
E. Wigren et al. / FEBS Letters 584 (2010) 878–882 879insight into the interaction between LMAN1 and MCFD2, and fur-
ther explain the consequences of mutations found in F5F8D pa-
tients we have determined the crystal structure of the complex
between the CRD of LMAN1 and MCFD2 and have characterized
F5F8D patient mutations.Resolution (Å) 2.45
Unique reﬂections 26465
Redundancy 11.8 (7.3)
Rsym (%) 12 (30)
I/r 17.6 (5.8)
Completeness (%) 98.9 (85.6)
hBi Wilson plot (Å2) 43.0
Reﬁnement
Number of reﬂections
Work set 25039 (1672)
Test set 1426 (87)
Number of atoms
Protein 4695
Water 109
Ca2+ ions 8
Rfactor 19.6 (26.1)
Rfree 24.7 (40.5)
Average B-factors (Å2)
Protein (CRD) 23.6
Protein (MCFD2) 27.8
Ca2+ ions 28.9
Water molecules 23.4
Bond length R.M.S.D. (Å) 0.016
Bond angle R.M.S.D. () 1.47
Ramachandran plot
Percentage in preferred regions 93.9
Percentage in additional allowed regions 5.2
Percentage in disallowed regions 0.8
Twin fraction
h, k, l 0.732
h  k, k, l 0.268
Numbers in parenthesis refer to highest resolution shell (2.51–2.45 Å).2. Materials and methods
2.1. Cloning
The cDNAs corresponding to the two EF-hand motifs of human
MCFD2 (residues 58–146) thus excluding the N-terminal unstruc-
tured region (MCFD2-N), and the CRD of human LMAN1 (residues
32–277) were ampliﬁed by PCR. The resulting fragments were
cloned into the expression vector pET-28a (Novagen), with a
thrombin cleavable 6 His-tag. An additional N-terminal GST-tag
was inserted into the vector containing the CRD. Full-length
MCFD2, excluding the signal sequence, was cloned as previously
described [7]. Amino acid substitutions were introduced into full-
length MCFD2 using the QuikChange site-directed mutagenesis
kit (Stratagene).
2.2. Expression and puriﬁcation
MCFD2 constructs and mutant variants were expressed in Esch-
erichia coli and puriﬁed by Ni–NTA afﬁnity chromatography as pre-
viously described [7]. LMAN1-CRD was expressed in E. coli at 16 C
for 60 hours in auto-induction media [18]. The cells were har-
vested by centrifugation, re-suspended in lysis-buffer (50 mM
Tris–HCl pH 8.5, 250 mM NaCl, 10 mM imidazole, 20 mM CaCl2
and 0.05% w/v PMSF), and lysed by sonication at 4 C. The proteins
were puriﬁed by Ni–NTA afﬁnity chromatography, followed by
afﬁnity puriﬁcation using glutathione-Sepharose 4B resin (Phar-
macia), and cleaved with thrombin to remove the GST-tag. After
mixing LMAN1-CRD with MCFD2-N, the LMAN1-CRD/MCFD2-N
complex was puriﬁed on a Superdex 75 column (GE Healthcare)
in 50 mM Tris–HCl pH 8.5 containing 250 mM NaCl and 20 mM
CaCl2.
2.3. Crystallization, data collection and data processing
Crystals of a complex comprising the LMAN1-CRD and MCFD2-
N were grown at 4 C using the sitting drop method by mixing 1 ll
of protein (6.5 mg/ml) with 0.5 ll of precipitation solution (20%
PEG6000, 0.1 M ammonium chloride 0.1 M Hepes, pH 7). Crystals
were ﬂash frozen in liquid nitrogen using 30% glycerol as cryopro-
tectant. X-ray diffraction data were collected to 2.45 Å resolution
at 100 K on beamline BM14 at the ESRF (Grenoble, France) using
a wavelength of 0.9537 Å and 0.2 oscillation angle. The data was
processed using XDS [19] and the CCP4-suite [20]. Table 1 shows
statistics of the data.
2.4. Structure determination and reﬁnement
Data reduction indicated the space group as P622 but further
analysis showed that the data were merohedrally twinned with
true space group P61. Initial phases were obtained by molecular
replacement using the program Phaser [21], with the crystal struc-
ture of the CRD of rat LMAN1 (PDB code 1R1Z [14]) as search mod-
el. One clear solution in space group P61 with two subunits in the
asymmetric unit was obtained. Attempts to position the MCFD2
subunits by molecular replacement with the NMR-model of
MCFD2 [7] were unsuccessful. However, the initial molecular
replacement electron density map of the CRD showed additional
electron density where, after density modiﬁcation with Parrot[22], two helices could be placed. Iterative model building in Coot
[23] and reﬁnement with Refmac5 [24] then allowed modelling of
the two MCFD2 molecules. The twin reﬁnement protocol imple-
mented in Refmac5 was employed in addition to anisotropic scal-
ing and simple bulk solvent correction. Tight NCS restraints were
applied for both the CRD and MCFD2; releasing these restraints
at the end did not lower the Rfree-value. The coordinates and struc-
ture factors have been deposited in the Protein Databank with
accession number 3LCP.
2.5. Circular dichroism spectroscopy
Circular dichroism (CD) measurements were conducted on a
JASCO J-810 spectropolarimeter using a cuvette of 0.1 cm path
length. All proteins were at a concentration of 0.1 mg/ml in
5 mM Bis–Tris buffer pH 7.4, with 5 mM CaCl2. The spectra were
recorded from 195 to 260 nm at 20 C. Ten scans were averaged
and corrected for the buffer spectrum. Thermal unfolding experi-
ments were performed by monitoring the CD signal at 222 nm be-
tween 20 and 90 C using a heating rate of 2 C/min. Melting points
(Tm) were calculated using sigmoidal ﬁt in GraphPad Prism
(GraphPad Software, Inc.).
3. Results
3.1. Structure
The structure of the complex of the CRD from LMAN1 and
MCFD2-N was determined by molecular replacement from
merohedrally twinned crystals to 2.45 Å resolution in space group
P61 with two complexes in the asymmetric unit. The electron
density map is continuous for the CRD from residue 41–274
880 E. Wigren et al. / FEBS Letters 584 (2010) 878–882(residue numbering include signal sequence), and with exceptions
of a few solvent exposed side chains, all residues are well-deﬁned.
The MCFD2 molecule is less well ordered and only residues 66–98
and residues 110–144 have been modelled (residue numbers in-
clude the signal sequence). The overall quality of the model is as
expected for this resolution and 94% of the residues are found in
the most favoured region of the Ramachandran plot (Table 1).
The structures of the two complexes in the asymmetric unit are
identical within the error limits of the electron density map.Fig. 1. (A) Structure of the complex. MCFD2 (blue) and the CRD (green). The
presumed carbohydrate binding site on the CRD is indicated with an arrow. (B)
Superposition of the MCFD2 structure determined by NMR (grey) and MCFD2 in the
complex (rainbow coloured). (C) The interface between MCFD2 (blue) and the CRD
(green). Interacting residues are labeled. Hydrogen bonds are shown as dashed
lines. Figs. 1 and 2A was prepared with PyMol [25].The CRD comprises two b-sheets packed into a b-sandwich
(Fig. 1A), with two calcium ions bound in the presumed carbohy-
drate binding site on the concave face. Comparison of the human
CRD in the complex with the structure of the free rat CRD protein
[14] shows that the N-terminal residues corresponding to residues
25–44 in the rat protein are disordered in the complex due to bind-
ing of MCFD2 at that location. Both structures of the rat CRD indi-
cated inherent ﬂexibility in these residues. No other major
structural perturbations in the CRD have occurred upon complex
formation; and superposition of the two structures gives an
R.M.S.D. of 0.32 Å for 227 Ca-atoms.
MCFD2 is composed of a ﬂexible N-terminal region and two EF-
hand calcium ion binding motifs. A comparison between the low-
est energy structure of MCFD2 determined by NMR [7] and MCFD2
in the complex shows deviations (Fig. 1B); 59 Ca-atoms can be
aligned with an R.M.S.D. of 2.3 Å. The NMR-analysis showed the
protein to be inherently very dynamic, the N-terminal 43 residues
of the mature protein could not be assigned to structure and the
loop consisting of residues 101–109 is very ﬂexible [7]. The ﬁrst
helix and Ca2+ binding loop are reasonably well aligned to the
NMR-structure whereas in the complex the C-terminal part of
the following bent helix is now straight. The ﬂexible loop is not
seen in the electron density. The last helix–Ca2+-loop–helix motif
is approximately aligned but the last turn of the terminal helix is
not observed.
Binding of MCFD2 to the CRD buries a surface area of 850 Å2,
17% of the surface area of the ordered part of MCFD2. Six hydro-
gen bonds, three ionic interactions and a few water-mediated
hydrogen bonds are formed upon complex formation. MCFD2 is
bound to the CRD on the opposite side relative to the carbohydrate
recognition site, close to the surface on the convex b-sheet sug-
gested to constitute a binding area for the protein part of the gly-
coprotein cargo (Fig. 1A and C). The main interaction area on the
CRD is made up of residues H43-F46, Y48-K49, S51-H56, Q59-
D61 and T63-F66, which encompass the ﬁrst ordered residues,
the ﬁrst b-strand in the convex sheet, which contains a turn of
310-helix structure in the middle, and the long loop that follows be-
fore b-strand 2. In MCFD2, several interacting residues are found in
the ﬁrst Ca2+-binding loop and the proceeding helix. These include
residues Y82 and D83, the latter is one of the Ca2+ ligands, and to-
gether with D89, makes salt bridges to K53 in the CRD. Other inter-
acting residues are G90-E92, where E92 is another Ca2+ ligand in
the ﬁrst EF-hand which is hydrogen bonded to K53 via a water
molecule, residues S94-T95, and T98-H99. In the ﬁrst helix of the
second EF-hand, residues L111, E114, I118, I121, D122 and L125
interact; E114 forms a salt bridge with K96 and D122 makes a
hydrogen bond with the side chain of Y48 on the CRD. In the
Ca2+ binding loop, the side chain of residue D129 forms a water
mediated bond to the R45 side chain, the side chain of N132 forms
hydrogen bonds with the carbonyl of P274 and the R45 side chain,
the main chain carbonyl of D133 forms a hydrogen bond to the
main chain nitrogen of F46, and G134 and Y135 pack against resi-
due F46 in the CRD (Fig. 1C).
In the crystal, MCFD2 also makes contact with another symme-
try-related CRD molecule, but this buries a smaller surface area of
590 Å2, includes only two hydrogen bonds and one salt bridge, and
is likely to be a crystallization artefact. A CRD/MCFD2 complex
structure, determined from untwinned crystals in another space
group just appeared in the Protein Data Bank (3A4U). Superposi-
tion shows the structures to be essentially the same, involving
the same interactions between the CRD and MCFD2.
3.2. CD measurements
It has been shown that the structural integrity of MCFD2
relies on the ability to bind calcium and formation of a small
Fig. 2. (A) The interface between MCFD2 (grey) and the CRD (blue) showing the positions of the F5F8D-causing mutations on MCFD2. The positions of the mutations analysed
by CD are coloured in orange (D81Y), pink (D89A), green (D122V), cyan (Y135N) and yellow (DSLQ). Mutations previously analysed in grey (D129E and I136T). (B) Far-UV CD
spectra of MCFD2 and F5F8D mutant variants. Mutant data are shown with the same colour coding as in (A), folded wild type in grey. (C) Thermal unfolding experiments
performed monitoring the CD signal at 222 nm. Mutant data are shown with the same colour coding as in (A), folded wild type in grey.
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mutations D81Y and D89A in the ﬁrst Ca2+ binding loop indicate
that both affect the stability of MCFD2. The spectrum of D81Y
has a proﬁle similar to that of the disordered apo state of wild-type
MCFD2 [7], indicating that this mutant has lost the ability to bind
Ca2+ and is disordered. The spectrum of D89A (Fig. 2) resembles
that of the Ca2+ bound form of wild-type MCFD2 with contribution
from a-helical structure with minima at 207 and 222 nm and a
change of sign from negative to positive CD at 197 nm. However,
the Tm of 43 C is signiﬁcantly lower than the 59 C for wild-type
MCFD2. Another patient mutation, Y135N [17] in the second Ca2+
binding loop, shows a spectrum indicating a lower a-helical con-
tent, albeit not completely disordered, and a Tm of 34 C. A non-
sense mutation causing deletion of the last three amino acids of
MCFD2 (DSLQ) results in a similar spectral proﬁle, consistent with
previous data [16] and due to very low stability a Tm could not be
determined. In contrast, the mutant D122V, positioned in the third
a-helix, has a spectrum and Tm value identical to wild-type
MCFD2. Thus, this mutation does not have a signiﬁcant structural
effect on MCFD2.
4. Discussion
LMAN1 and MCFD2 are present primarily in complex with each
other with a 1:1 stoichiometry in vivo [5]. The binding constant for
CRD and MCFD2 is 1.6  108 M [6] and for CRD and N-terminal
truncated MCFD2 in the same order (unpublished data) so the lim-
ited 850 Å2 surface area buried upon complex formation is surpris-
ing. The binding of MCFD2 does not induce any major structural
changes in the CRD and thus it most probably acts as co-receptor
in the transport of FV and FVIII by direct interaction with cargo
rather than through modulation of the binding of cargo to the
CRD. This is consistent with data showing that MCFD2 bearing
the D129E mutation, which disrupts the LMAN1–MCFD2 interac-
tion, can still be cross-linked to FVIII [5]. Binding of the cargo in
the carbohydrate binding site on the CRD and to the ordered partof MCFD2, requires the cargo to reach over a long stretch on the
CRD – more than 45 Å (Fig. 1A). Even if the disordered N-terminal
residues and the dynamic loop between the two EF-hands in
MCFD2 would constitute the cargo binding residues, the distance
to the carbohydrate binding site on the CRD would be of the same
order. A perhaps more likely scenario could be that while binding
with its sugar moieties to the CRD, the cargo interacts with MCFD2
bound to a neighbouring CRD. LMAN1 assembles into hexamers
during cargo transport [9], but in solution the heterodimeric com-
plex of the CRD with MCFD2 shows no signs of oligomerization.
Analysis of the packing interactions in the crystal does not reveal
any assemblies corresponding to oligomeric receptor complexes.
That is not surprising as earlier studies have shown that oligomer-
ization is mediated by the stalk domain [9].
All known LMAN1 mutations are null alleles except three mis-
sense mutations. One of these changes the starting methionine to
a threonine and is not translated, while the second, C475R, affects
oligomerisation [2]. The third, W67S, which was shown to interfere
both with MCFD2 and mannose binding [15], would disrupt the
packing of the LMAN1 hydrophobic core, destabilizing the protein.
None of these residues are involved in interactions with MCFD2.
Nine of the F5F8D mutations inMCFD2 disrupt the open reading
frame, while the others are substitution mutants. One of these cre-
ates a stop codon (DSLQ), deleting the last three residues of the
protein, which was shown to impede binding to LMAN1 in HeLa
cells [16]. Two mutations, D129E and I136T, are located in the sec-
ond EF-hand motif, and have been shown to abolish the interaction
between MCFD2 and LMAN1 in HeLa cells [4]. This was explained
by NMR studies which revealed both to be predominantly disor-
dered. F5F8D mutations D81Y, D89A and D122V were shown by
co-immunoprecipitation in COS1 cells to abolish MCFD2 binding
to LMAN1 [2].
As seen from the CD-data, the MCFD2 mutations D81Y, D129E,
I136T, and DSLQ all give rise to destabilized proteins which result
in F5F8D. D81 and D129 are Ca2+ ligands and upon mutation Ca2+
can no longer bind, preventing formation of a stable MCFD2. I136
882 E. Wigren et al. / FEBS Letters 584 (2010) 878–882is part of the second Ca2+ binding loop and participates in the small
hydrophobic core of the protein. Structural disturbance by muta-
tion of this residue would thus both impede Ca2+ binding and dis-
turb packing of the hydrophobic core. The instability of the DSLQ
mutation is more difﬁcult to understand, these residues are
disordered in the complex structure, while in the free MCFD2 they
interact with the disordered loop between the two EF-hands; the
C-terminal carboxyl group forms an ion pair with K102 in the loop.
It is possible that this interaction is important for stability of
MCFD2 and that the unstructured protein resulting from the muta-
tion is unable to bind to LMAN1. Mutants D89A and Y135N are less
severely destabilized but are unable to bind to LMAN1. The side
chain of D89 caps the N-terminus of the helix after the ﬁrst Ca2+
binding loop and forms a hydrogen bond to a water ligand of the
Ca2+ ion. Presumably loss of these interactions gives rise to some
destabilization of the D89A mutant as seen in the lowered Tm-va-
lue. Furthermore, D89 forms a salt bridge with K53 of the CRD,
explaining the loss of LMAN binding [2] and F5F8D for the muta-
tion. The side chain of Y135, which is located in the second Ca2+
binding loop, is involved in hydrophobic interactions with L87
and the mutation Y135N can thus cause destabilization of the mu-
tated protein. In addition, in the complex, Y135 packs against F46
in the CRD which would weaken the interaction of Y135N to
LMAN1, the combination leading to F5F8D. Finally, the D122V mu-
tant CD-spectra and melting point are indistinguishable from the
wild type MCFD2. D122 is located in the middle of helix three
and forms a hydrogen bond to Y48 and an ionic interaction with
K49 in the CRD. The inability to engage in these interactions se-
verely impedes binding to LMAN1 and results in F5F8D for this
mutant.
In conclusion, most of the known F5F8D substitution mutations
in MCFD2 cause destabilization of its already inherently ﬂexible
structure or loss of interactions with LMAN1. Both mutation effects
result in a signiﬁcantly lower number of competent receptor com-
plexes and inefﬁcient transport of coagulation factors V and VIII
from the ER. Interestingly, none of the characterized F5F8D muta-
tions can be implicated in cargo binding.
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